1. Pyrazinamide resistance in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Abkhazia
- Author
-
Pardini M., Varaine F., Hewison C., Iona E., Pataracchia M., Orefici G., Fattorini L., Oggioni M. R., Meacci F., D'Amato V., Andrew P. W., Barer M., Yesilkaya H., Rinder H., Rusch-Gerdes S., Niemann S., Orru G., Bonnet M., Jarosz T., Pardini M., Varaine F., Hewison C., Iona E., Pataracchia M., Orefici G., Fattorini L., Oggioni M.R., Meacci F., D'Amato V., Andrew P.W., Barer M., Yesilkaya H., Rinder H., Rusch-Gerdes S., Niemann S., Orru G., Bonnet M., and Jarosz T.
- Subjects
Pharmacology ,biology ,business.industry ,Antitubercular Agents ,Drug resistance ,Microbial Sensitivity Tests ,Mycobacterium tuberculosis ,Pyrazinamide ,biochemical phenomena, metabolism, and nutrition ,biology.organism_classification ,bacterial infections and mycoses ,Microbiology ,Multiple drug resistance ,Infectious Diseases ,Oncology ,Drug Resistance, Multiple, Bacterial ,medicine ,Pharmacology (medical) ,tuberculosis, drug resistance ,business ,medicine.drug - Abstract
The emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, i.e. strains resistant at least to isoniazid (INH) and rifampin (RMP), the two most powerful first-line drugs for the treatment of tuberculosis (TB), represents a worldwide health care problem. Patients with MDR strains should receive therapy based on individual drug susceptibility testing (DST) 1 including residual first-line (streptomycin, SM; ethambutol, EMB; and pyrazinamide, PZA) and second-line (ofloxacin, kanamycin, capreomycin, ethionamide, p-aminosalicylic acid, cycloserine) anti-TB drugs.
- Published
- 2007